A Phase 2 interventional study of HSK55718 dose level1 and HSK55718 dose level2 in Pain After Surgery, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Pain with a site in China — 65 open to participants now, 71 under way, 2 of them phase 3. Pain · China.
Among the 246 studies in Pain with a site in China, this one is the 65th largest by planned enrollment of the 211 interventional ones that give a count, is one of 24 that started in 2026, is one of 18 in phase 2, reaches primary completion later than 29 of the 70 other live ones, and was the 230th registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →65 of the 246 studies in Pain with a site in China are open now. Recruiting first, the newest first:
Yi Duan · Sites in China
Ages 18–75
Novartis Pharmaceuticals · Sites in China
Ages 18+
Yingyong Zhou,MD,PhD · Sites in China
Ages 18+
Lijiang Lv · Sites in China
Ages 18–60
Beijing Tiantan Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 27 · Phase 3 26 · Phase 4 30
First in 1992; this study’s year is marked. 24 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 120 across the 211 interventional studies, 169 across the 34 observational. Of the 122 that completed or were terminated, 17 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 246 have an industry lead sponsor. The 10 most frequent:
Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.
Haisco Pharmaceutical Group Co., Ltd. has 3 studies filed under Pain — fewer than ten, so there is no comparison to draw.
29 of the studies in Pain with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07872826Phase 3The Third Xiangya Hospital of Central South UniversityA Clinical Trial Evaluating the Efficacy and Safety of Local Infiltration of RF16001 for Injection for Analgesia After Total Hip Arthroplasty in China | 2027-06-30 |
| NCT07533786Haisco Pharmaceutical Group Co., Ltd.A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery | 2026-11-22 |
| NCT06553495Jie ChenA Comparative Analysis of Intertransverse Nerve Block and Paravertebral Nerve Block in Endoscopic Hepatectomy | 2026-11-30 |
| NCT07557823Second Affiliated Hospital, School of Medicine, Zhejiang UniversityTranscutaneous Auricular Vagus Nerve Stimulation Combined With Cervical Epidural Injection for Cervical Radiculopathy | 2026-12-30 |
| NCT07099157Peking University Third HospitalEfficacy and Safety of Brivudine in the Treatment of Herpes Zoster | 2026-12-31 |
Add all 29 to your calendar (.ics) → With an account.
Among the 246 studies in Pain with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, double-dummy, placebo/active-controlled study. 200 subjects undergoing abdominal surgery under general anesthesia are planned to be enrolled and randomized into the HSK55718 group, morphine group, and placebo group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HSK55718 dose level1
Drug: HSK55718 dose level2
Drug: HSK55718 dose level 3
Drug: Placebo control
Drug: morphine
Patients administrated with HSK55718 at dose level 1
Patients administrated with HSK55718 at dose level 2
Patients administrated with HSK55718 at dose level 3
Patients administrated with placebo
Patients administrated with morphine
Sum of Pain Intensity Differences (SPID)
Time frame: 24 hours
Sum of Pain Intensity Differences (SPID) in other time frame
Time frame: 0-12 hours, 12-24 hours, 24-48 hours, 48 hours
Number of times rescue analgesic medications were administered.
Time frame: 48 hours
Time to Pain Relief
Time frame: 0-48 hours
Postoperative Analgesia Satisfaction Score
Time frame: 48 hours
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.
Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 6 months is below that.
Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HSK55718
Haisco Pharmaceutical Group Co., Ltd. →